| Sequence 1: | NP_002323.2 | Gene: | LRP1 / 4035 | HGNCID: | 6692 | Length: | 4544 | Species: | Homo sapiens |
|---|---|---|---|---|---|---|---|---|---|
| Sequence 2: | NP_001260800.2 | Gene: | LRP1 / 35799 | FlyBaseID: | FBgn0053087 | Length: | 4752 | Species: | Drosophila melanogaster |
| Alignment Length: | 4909 | Identity: | 1760/4909 - (35%) |
|---|---|---|---|
| Similarity: | 2512/4909 - (51%) | Gaps: | 660/4909 - (13%) |
- Green bases have known domain annotations that are detailed below.
|
Human 27 CSPKQFACRDQITCISKGWRCDGERDCPDGSDEAPEICPQSKAQRCQPNEHNCLGTELCVPMSRL 91
Human 92 CNGVQDCMDG--SDE-------GPHCRELQGN--------------------------------C 115
Human 116 SRLGCQHHCVPTLDGPTCYCNSSFQLQADGKT-CKDFDECSVYGTCSQLCTNTDGSFICGCVEGY 179
Human 180 LLQPDNRSCKAKNEPVDRPPVLLIANSQNILATYLSGAQVSTITPTSTRQTT------------- 231
Human 232 -----------AMDFSYANETVC-----WVHVGDSAAQTQLKCARMPGLKGFVDEHTINISLSL- 279
Human 280 ------HHVEQMAIDWLTGNFYFVDDIDDRIFVCNRNGDTCVTLLDLELYNP-KGIALDPAMGKV 337
Human 338 FFTDYGQIPKVERCDMDGQNRTKLVDSKIVFPHGITLDLVSRLVYWADAYLDYIEVVDYEGKGRQ 402
Human 403 TIIQ----GILIEHLYGLTVFENYLYATNSDNANAQQKTSVIRVNRFNSTEYQVVTRVDKGGALH 463
Human 464 IYHQRRQPRVRSHACENDQYGKPGGCSDICL--LANSHKARTCRCRSGFSLGSDGKSCKKPEHEL 526
Human 527 FLVYGKGRPGIIRGMDMG----------AKVPDEHMIPIENLMNPRALDFHAETGFIYF--ADT- 578
Human 579 --------TSYLIGRQKIDGTERETILKDGIHNVEGVAVDWMGDNLYWTDDGPKKTISVARLEKA 635
Human 636 AQTRKTLIEGKMTHPRAIVVDPLNGWMYWTDWEEDPKDSRRGRLERAWMDGSHRDIF---VTSKT 697
Human 698 VLWPNGLSLDIPAGRLYWVDAFYDRIETILLNGTDRKIVYEGPELNHAFGLCHHGNYLFWTEYRS 762
Human 763 GSVYRLERGVGGA----PPTVTLLRSERPPIFEIRMYDAQQQQVGTNKCRVNNGGCSSLCLATPG 823
Human 824 SRQCACAEDQVLDADGVTCLANPSYVPP---PQCQPGEFACANSR-CIQERWKCDGDNDC---LD 881
Human 882 NSDEAPALCHQHTC-PSDRFKCENNRCIPNRWLCDGDNDCGNSEDESNATCSARTCPPNQFSC-A 944
Human 945 SGRCIPISWTCDLDDDCG--DRSDESASCAYPTCFPLTQFTCNNGRCININWRCDNDNDCGDNSD 1007
Human 1008 EAGCSHSCSSTQFKCNSGRCIPEHWTCDGDNDCGDYSDETHANCTNQATRPP------GGCHTDE 1066
Human 1067 FQCRLDGLCIPLRWRCDGDTDCMDSSDEKSCEGVTHVCDPSVKFGCKDSARCISKAWVCDGDNDC 1131
Human 1132 EDNSDEENCESLACRPPSHPCANNTSVCLPPDKLCDGNDDCGDGSDEGELC-DQCSLNNGGCSHN 1195
Human 1196 CSVAPGEGIVCSCPLGMELGPDNHTCQIQSYCAKHLKCSQKCDQNKFSVKCSCYEGWVLEPDGES 1260
Human 1261 CRSLDPFKPFIIFSNRHEIRRIDLHKGDYSVLVPGLRNTIALDF---HLSQSALYWTDVVEDKIY 1322
Human 1323 RGKLLDNGALTSFEVVIQYGLATPEGLAVDWIAGNIYWVESNLDQIEVAKLDGTLRTTLLAGDIE 1387
Human 1388 HPRAIALDPRDGILFWTDWDASLPRIEAASMSGAGRRTVHRETG-SGGWPNGLTVDYLEKRILWI 1451
Human 1452 DARSDAIYSARYDGSGHMEVLRGHEFLSHPFAVTLYGGEVYWTDWRTNTLAKANKWTGHNVTVVQ 1516
Human 1517 RTNTQPFDLQVYHPSRQPMAPNPC-EANGGQGPCSHLCLINYNRTVSCACPHLMKLHKDN-TTCY 1579
Human 1580 EFKKFLLYARQMEIRGVDLDAPYYNYIISFTVPDIDNVTVL------DYDAREQRVYWSDVRTQA 1638
Human 1639 IKRAFINGTGVETVVSADLPNAHGLAVDWVSRNLFWTSYDTNKKQINVARLDGSFKNAVVQGLEQ 1703
Human 1704 PHGLVVHPLRGKLYW----TDG--DNISMANMDGSNRTLLFSGQKGPVGLAIDFPESKLYWISSG 1762
Human 1763 NHTINRCNLDGSGLEVIDAMRSQLGKA---------TALAIMGDKLWWADQVSEKMGTCSKADGS 1818
Human 1819 GSVVLRNSTTLVMHMKVYDESIQLDHKGTNPCS--VNNGDCSQLCLPTSETTRSCMCTAGYSLR- 1880
Human 1881 SGQQACEGVGSFLLYSVHEGIRGIP-LDPNDKSD----ALVPVSGTSLAVGIDFHAENDTIYWVD 1940
Human 1941 MGLSTISRAKRDQTWREDVV--TNGIGRVE-----GIAVDWIAGNIYWTDQGFDVIEVARLNGSF 1998
Human 1999 RYVVISQGLDKPRAITVHPEKGYLFWTEWGQYPRIERSRLDGTERVVLVN-VSISWPNG-ISVDY 2061
Human 2062 QDGKLYWCDARTDKIERIDLETGENREVVLSSNNMDMFSVSVFEDFIYWSDRTHANGSIKRGSKD 2126
Human 2127 NATDS-VPLRTGIGVQLKDIKVFNRDRQKGTNVCAVANGGCQQLCLYRGRGQRACACAHGMLAED 2190
Human 2191 GASCREYAGYLLYSERTILKSIHLSDERNLNAPVQPFEDPEHMKNVIALAFDYRAGTSPGTPNRI 2255
Human 2256 FFSDIHFGNIQQINDDGSRRITIVENVGSVEGLAYHRGWDTLYWTSYTTSTI----TRHTVDQTR 2316
Human 2317 PGAFERETVITMSGDDHPRAFVLDECQNLMFWTNWNEQHPSIMRAALSGANVLTLIEKDIRTPNG 2381
Human 2382 LAIDHRAEKLYFSDATLDKIERCEYDGSHRYVILKSEPVHPFGLAVYGEHIFWTDWVRRAVQRAN 2446
Human 2447 KHVGSNMKLLRVDIPQQPMGIIAVANDTNSCELSPCRINNGGCQDLCLLTHQGHVNCSCRGGRIL 2511
Human 2512 QDDLTCRA-VNSSCRAQDEFECANGECINFSLTCDGVPHCKDKSDEKPSYCNSRRCKKTFRQCSN 2575
Human 2576 GRCVSNMLWCNGADDCGDGSDEIP----C-----------NKTACGVGEFRCRDGTCIGNSSRCN 2625
Human 2626 QFVDCEDASDEMNCSATDCSSYFRLGVKGVLFQPCERTSLCYAPSWVCDGANDCGDYSDERDCPG 2690
Human 2691 VKRPRCPLNYFACPSGRCIPMSWTCDKEDDCEHGEDETHCNKFCSEAQFECQNHRCISKQWLCDG 2755
Human 2756 SDDCGDGSDEAAHCEGKTCGPSSFSCPGTHVCVPERWLCDGDKDCADG-ADESI------AAGCL 2813
Human 2814 YNSTCDDREFMCQNRQCIPKHFVCDHDRDCADGSDESPEC----EYPTC--GPSEFRCANGRCLS 2872
Human 2873 SRQWECDGENDCHDQSDEAPKNPHCTSQEHKCNASSQFLCSSGRCVAEALLCNGQDDCGDSSDER 2937
Human 2938 GCHINECLSRKLSGCSQDCEDLKIGFKCRCRPGFR-LKDDGRTCADVDECSTTFPCSQRCINTHG 3001
Human 3002 SYKCLCVEGYAPRGGDPHSCKAVTDEEPFLIFANRYYLRKLNLDGSNYTLLKQGLNNAVALDFDY 3066
Human 3067 REQMIYWTDVTTQGSMIRRMHLNGSNVQVLHRTGLSNPDGLAVDWVGGNLYWCDKGRDTIEVSKL 3131
Human 3132 NGAYRTVLVSSGLREPRALVVDVQNGYLYWTDWGDHSLIGRIGMDGSSRSVIVDTKITWPNGLTL 3196
Human 3197 DYVTERIYWADAREDYIEFASLDGSNRHVVLSQDI------PHIFALTLFEDYVYWTDWETKSIN 3255
Human 3256 RAHKTTGTNKTLLISTLHRPMDLHVFHALRQPD-VPNHPCKVNNGGCSNLCLLSPGGG-HKCACP 3318
Human 3319 TNFYLGSDGRTCVSNCTASQFVCKND-KCIPFWWKCDTEDDCGDHSDEPPDCPEFKCRPGQFQCS 3382
Human 3383 TGICTNPAFICDGDNDCQDNSDEANCDIHVCLPSQFKCTNTNR----CIPGIFRCNGQDNCGDGE 3443
Human 3444 DERDCPEVTCAPNQFQCSITKRCIPRVWVCDRDNDCVDGSDEPANCTQMTCGVDEFRCKDSGRCI 3508
Human 3509 PARWKCDGEDDCGDGSDEPKEEC--DERTCEPYQFRCKNNRCVPGRWQCDYDNDCGDNSDEESCT 3571
Human 3572 PRPCSESEFSCANGRCIAGRWKCDGDHDCADGSDEKDCTPRCDMDQFQCKS-GHCIPLRWRCDAD 3635
Human 3636 ADCMDGSDEEACGTGVRTCPLDEFQCNNTLCKPLAWKCDGEDDCGDNSDENPEECARFVCPPNRP 3700
Human 3701 FRCKNDRVCLWIGRQCDGTDNCGDGTDEED--CEPPTAHTTHCKDKKEFLCRNQRCLSSSLRCNM 3763
Human 3764 FDDCGDGSDEEDCSIDPKLTSCATNASICGDEARCVRTEKAAYCACRSGFHTVPGQPGCQDINEC 3828
Human 3829 LRFGTCSQLCNNTKGGHL-CSCARNFMK---THNTCKAEGSEYQVLYIADDNEIRSLFPGHPHSA 3889
Human 3890 YEQAFQGDESVRIDAMDVHV--KAGRVYWTNWHTGTISYRSLPPAAPPTTSNRHRRQIDRGVTHL 3952
Human 3953 NISGLKMPRGIAIDWVAGNVYWTDSGRDVIEVAQMKGENRKTLIS-GMIDEPHAIVVDPLRGTMY 4016
Human 4017 WSDWGNHPKIETAAMDGTLRETLVQDNIQWPTGLAVDYHNERLYWADAKLSVIGSIRLNGTD-PI 4080
Human 4081 VAADSKRGLSHPFSIDVFEDYIYGVTYINNRVFKIHKFGHSPLVNLTGGLSHASDVVLYHQHKQ- 4144
Human 4145 PEVTNPCDRKKCE---WLCLLSPSGPV---CTCPNGKRL-DNGTC-----VP------------- 4184
Human 4185 ----VP------------------------------------SPTPPP--------------DAP 4195
Human 4196 RPGTCNLQCFNGGSCFLNARRQPKCRCQPRYTGDKCELDQCWEHCR-----NGGTCAASPSGMPT 4255
Human 4256 CRCPTGFTGPKCTQQVCAGYCANNSTCTVNQGNQPQCRCLPGFLGDRCQYRQCSGYCENFGTCQM 4320
Human 4321 AADGSRQCRCTAYFEGSRCEVNKCSR-----------------CL------EGACVVNKQSGDVT 4362
Human 4363 CNCTDGRVAPSCL-------TCVGHCSNGGSCTMNSKMMPECQC-----------PPHMTGPRCE 4409
Human 4410 --------------------------EHVFSQQQP---GHIASILIPLLLLLLLV--LVAGVVFW 4443
Human 4444 YKR-RVQGAKGFQHQRMTNGAMNVEIGNPTYKMYEGGEPDDVGGLLDAD----FALDPDKPTNFT 4503
Human 4504 NPVYATLYMGGHGS------RHSLASTDEKRELL 4531 |
| Gene | Sequence | Domain | Region | External ID | Identity |
|---|---|---|---|---|---|
| LRP1 | NP_002323.2 | LDLa | 26..59 | CDD:197566 | 14/31 (45%) |
| Ldl_recept_a | 71..104 | CDD:395011 | 11/34 (32%) | ||
| FXa_inhibition | 119..148 | CDD:464251 | 8/29 (28%) | ||
| FXa_inhibition | 158..188 | CDD:464251 | 16/29 (55%) | ||
| LY | 275..314 | CDD:214531 | 10/45 (22%) | ||
| LDL-receptor class B 1 | 292..334 | 12/42 (29%) | |||
| LY | 316..358 | CDD:214531 | 13/42 (31%) | ||
| LDL-receptor class B 2 | 335..378 | 18/42 (43%) | |||
| LY | 361..401 | CDD:214531 | 19/39 (49%) | ||
| LDL-receptor class B 3 | 379..422 | 17/46 (37%) | |||
| FXa_inhibition | 486..519 | CDD:464251 | 8/34 (24%) | ||
| LY | 551..593 | CDD:214531 | 11/52 (21%) | ||
| LDL-receptor class B 4 | 571..613 | 13/52 (25%) | |||
| LY | 594..633 | CDD:214531 | 15/38 (39%) | ||
| LDL-receptor class B 5 | 614..659 | 13/44 (30%) | |||
| LY | 640..689 | CDD:214531 | 14/48 (29%) | ||
| LDL-receptor class B 6 | 660..710 | 16/52 (31%) | |||
| LY | <700..733 | CDD:214531 | 13/32 (41%) | ||
| LDL-receptor class B 7 | 711..754 | 11/42 (26%) | |||
| FXa_inhibition | 807..842 | CDD:464251 | 9/34 (26%) | ||
| LDLa | 853..885 | CDD:197566 | 12/35 (34%) | ||
| LDLa | 895..928 | CDD:238060 | 10/33 (30%) | ||
| LDLa | 935..967 | CDD:197566 | 17/34 (50%) | ||
| LDLa | 978..1011 | CDD:238060 | 15/32 (47%) | ||
| LDLa | 1015..1048 | CDD:238060 | 13/32 (41%) | ||
| LDLa | 1062..1097 | CDD:238060 | 15/34 (44%) | ||
| LDLa | 1104..1140 | CDD:238060 | 1/35 (3%) | ||
| LDLa | 1145..1178 | CDD:238060 | 12/32 (38%) | ||
| FXa_inhibition | 1185..1221 | CDD:464251 | 13/35 (37%) | ||
| LDL-receptor class B 8 | 1309..1355 | 26/45 (58%) | |||
| Vgb | 1310..>1503 | CDD:443399 | 118/193 (61%) | ||
| LY | 1336..1376 | CDD:214531 | 27/39 (69%) | ||
| LDL-receptor class B 9 | 1356..1398 | 29/41 (71%) | |||
| LY | 1380..1423 | CDD:214531 | 31/42 (74%) | ||
| LDL-receptor class B 10 | 1399..1445 | 30/46 (65%) | |||
| LDL-receptor class B 11 | 1446..1490 | 24/43 (56%) | |||
| LDL-receptor class B 12 | 1491..1531 | 24/39 (62%) | |||
| LY | 1613..1649 | CDD:214531 | 11/41 (27%) | ||
| LDL-receptor class B 13 | 1627..1669 | 13/41 (32%) | |||
| LY | 1650..1693 | CDD:214531 | 13/42 (31%) | ||
| LDL-receptor class B 14 | 1670..1713 | 11/42 (26%) | |||
| LY | 1697..1734 | CDD:214531 | 13/42 (31%) | ||
| LDL-receptor class B 15 | 1714..1753 | 15/44 (34%) | |||
| LY | 1734..1775 | CDD:214531 | 8/40 (20%) | ||
| LDL-receptor class B 16 | 1754..1798 | 9/52 (17%) | |||
| FXa_inhibition | 1850..1886 | CDD:464251 | 13/38 (34%) | ||
| YncE | 1872..2084 | CDD:442618 | 90/226 (40%) | ||
| LDL-receptor class B 17 | 1934..1976 | 22/48 (46%) | |||
| LY | 1959..1999 | CDD:214531 | 22/46 (48%) | ||
| LDL-receptor class B 18 | 1977..2019 | 25/41 (61%) | |||
| LDL-receptor class B 19 | 2020..2063 | 15/44 (34%) | |||
| Ldl_recept_b | 2020..2061 | CDD:459654 | 14/42 (33%) | ||
| LY | 2045..2087 | CDD:214531 | 14/43 (33%) | ||
| LDL-receptor class B 20 | 2064..2107 | 10/42 (24%) | |||
| FXa_inhibition | 2159..2194 | CDD:464251 | 19/34 (56%) | ||
| LDL-receptor class B 21 | 2253..2294 | 12/40 (30%) | |||
| LDL-receptor class B 22 | 2295..2343 | 13/51 (25%) | |||
| LDL-receptor class B 23 | 2344..2388 | 18/43 (42%) | |||
| Ldl_recept_b | 2344..2386 | CDD:459654 | 17/41 (41%) | ||
| LY | 2370..2411 | CDD:214531 | 22/40 (55%) | ||
| LDL-receptor class B 24 | 2389..2431 | 25/41 (61%) | |||
| LDL-receptor class B 25 | 2432..2473 | 21/40 (53%) | |||
| FXa_inhibition | 2482..2517 | CDD:464251 | 13/34 (38%) | ||
| LDLa | 2527..2557 | CDD:238060 | 15/29 (52%) | ||
| LDLa | 2566..2600 | CDD:238060 | 16/37 (43%) | ||
| LDLa | 2605..2639 | CDD:238060 | 13/33 (39%) | ||
| LDLa | <2666..2688 | CDD:238060 | 11/21 (52%) | ||
| LDLa | 2696..2730 | CDD:238060 | 17/33 (52%) | ||
| LDLa | 2734..2765 | CDD:197566 | 15/30 (50%) | ||
| LDLa | 2773..2806 | CDD:197566 | 14/33 (42%) | ||
| LDLa | 2817..2849 | CDD:197566 | 12/31 (39%) | ||
| LDLa | 2857..2890 | CDD:197566 | 13/34 (38%) | ||
| LDLa | 2907..2939 | CDD:238060 | 13/31 (42%) | ||
| cEGF | 2964..2985 | CDD:463661 | 8/21 (38%) | ||
| EGF_CA | 2982..>3011 | CDD:214542 | 19/28 (68%) | ||
| LY | 3049..3093 | CDD:214531 | 17/43 (40%) | ||
| LDL-receptor class B 26 | 3069..3113 | 21/43 (49%) | |||
| LY | 3094..3136 | CDD:214531 | 30/41 (73%) | ||
| LDL-receptor class B 27 | 3114..3156 | 25/41 (61%) | |||
| LY | 3138..3180 | CDD:214531 | 19/41 (46%) | ||
| LDL-receptor class B 28 | 3157..3200 | 18/42 (43%) | |||
| LY | 3182..3223 | CDD:214531 | 17/40 (43%) | ||
| LDL-receptor class B 29 | 3201..3243 | 17/47 (36%) | |||
| LY | 3224..3264 | CDD:214531 | 17/45 (38%) | ||
| LDL-receptor class B 30 | 3244..3284 | 24/39 (62%) | |||
| FXa_inhibition | 3294..3330 | CDD:464251 | 20/36 (56%) | ||
| LDLa | 3334..3365 | CDD:238060 | 21/31 (68%) | ||
| LDLa | 3374..3408 | CDD:238060 | 18/33 (55%) | ||
| LDLa | 3413..3448 | CDD:238060 | 13/38 (34%) | ||
| LDLa | 3452..3485 | CDD:197566 | 18/32 (56%) | ||
| LDLa | 3493..3526 | CDD:197566 | 17/32 (53%) | ||
| LDLa | 3536..3570 | CDD:238060 | 21/33 (64%) | ||
| LDLa | 3575..3609 | CDD:238060 | 18/33 (55%) | ||
| LDLa | 3613..3647 | CDD:238060 | 16/34 (47%) | ||
| LDLa | 3653..3685 | CDD:197566 | 17/31 (55%) | ||
| LDLa | 3695..3731 | CDD:238060 | 14/37 (38%) | ||
| LDLa | 3746..3776 | CDD:238060 | 13/29 (45%) | ||
| YncE | 3862..4064 | CDD:442618 | 63/204 (31%) | ||
| LDL-receptor class B 31 | 3912..3954 | 8/41 (20%) | |||
| Recognition site for proteolytical processing. /evidence=ECO:0000255 | 3940..3943 | 1/2 (50%) | |||
| LY | 3955..3992 | CDD:214531 | 11/36 (31%) | ||
| LDL-receptor class B 32 | 3970..4012 | 14/42 (33%) | |||
| LDL-receptor class B 33 | 4013..4056 | 15/42 (36%) | |||
| Ldl_recept_b | 4013..4054 | CDD:459654 | 13/40 (33%) | ||
| LY | 4037..4078 | CDD:214531 | 18/40 (45%) | ||
| LDL-receptor class B 34 | 4057..4101 | 20/44 (45%) | |||
| Interaction with MAFB. /evidence=ECO:0000250|UniProtKB:Q91ZX7 | 4445..4544 | 36/98 (37%) | |||
| NPXY motif | 4502..4507 | 3/4 (75%) | |||
| LRP1 | NP_001260800.2 | LDLa | 87..118 | CDD:197566 | 13/30 (43%) |
| LDLa | 126..163 | CDD:238060 | 10/38 (26%) | ||
| EGF_CA | 246..283 | CDD:214542 | 9/36 (25%) | ||
| Ldl_recept_b | 449..487 | CDD:459654 | 13/41 (32%) | ||
| LY | 472..513 | CDD:214531 | 8/40 (20%) | ||
| LY | 817..852 | CDD:214531 | 7/38 (18%) | ||
| LDLa | 1057..1092 | CDD:197566 | 11/34 (32%) | ||
| LDLa | 1104..1134 | CDD:238060 | 11/35 (31%) | ||
| LDLa | 1191..1226 | CDD:238060 | 6/34 (18%) | ||
| FXa_inhibition | 1289..1317 | CDD:464251 | 8/27 (30%) | ||
| LY | 1434..1476 | CDD:214531 | 28/41 (68%) | ||
| LY | 1477..1521 | CDD:214531 | 25/44 (57%) | ||
| LY | 1533..1567 | CDD:214531 | 18/33 (55%) | ||
| LY | 1568..1611 | CDD:214531 | 24/43 (56%) | ||
| FXa_inhibition | 1639..1676 | CDD:464251 | 12/36 (33%) | ||
| LY | 1751..1789 | CDD:214531 | 11/43 (26%) | ||
| LY | 1794..1838 | CDD:214531 | 10/43 (23%) | ||
| LY | 2078..2112 | CDD:214531 | 12/34 (35%) | ||
| NHL | <2082..>2152 | CDD:302697 | 23/71 (32%) | ||
| NHL repeat | 2082..2120 | CDD:271320 | 13/39 (33%) | ||
| FXa_inhibition | 2269..2303 | CDD:464251 | 13/33 (39%) | ||
| LY | 2430..2471 | CDD:214531 | 22/40 (55%) | ||
| LY | 2475..2517 | CDD:214531 | 21/41 (51%) | ||
| LDLa | 2630..2661 | CDD:238060 | 15/45 (33%) | ||
| LDLa | 2671..2702 | CDD:238060 | 13/30 (43%) | ||
| LDLa | 2727..2759 | CDD:238060 | 13/31 (42%) | ||
| LDLa | 2773..2802 | CDD:238060 | 13/28 (46%) | ||
| LDLa | 2810..2844 | CDD:238060 | 16/33 (48%) | ||
| LDLa | 2848..2878 | CDD:238060 | 12/36 (33%) | ||
| LDLa | 2887..2916 | CDD:197566 | 13/32 (41%) | ||
| LDLa | 2938..2969 | CDD:197566 | 11/30 (37%) | ||
| LDLa | 2989..3015 | CDD:197566 | 12/25 (48%) | ||
| LDLa | 3030..3061 | CDD:238060 | 15/31 (48%) | ||
| EGF_CA | 3062..>3091 | CDD:214542 | 14/28 (50%) | ||
| EGF_CA | 3103..3141 | CDD:214542 | 16/37 (43%) | ||
| LY | 3212..3254 | CDD:214531 | 16/41 (39%) | ||
| Ldl_recept_b | 3275..3314 | CDD:459654 | 17/44 (39%) | ||
| LY | 3299..3340 | CDD:214531 | 22/40 (55%) | ||
| LY | 3354..3389 | CDD:214531 | 19/35 (54%) | ||
| LDLa | 3458..3490 | CDD:238060 | 13/35 (37%) | ||
| LDLa | 3499..3533 | CDD:238060 | 16/33 (48%) | ||
| LDLa | 3582..3616 | CDD:238060 | 16/35 (46%) | ||
| LDLa | 3621..3652 | CDD:197566 | 18/30 (60%) | ||
| LDLa | 3663..3697 | CDD:238060 | 13/34 (38%) | ||
| LDLa | 3702..3736 | CDD:238060 | 15/33 (45%) | ||
| LDLa | 3776..3808 | CDD:197566 | 11/33 (33%) | ||
| LDLa | 3818..3849 | CDD:197566 | 9/30 (30%) | ||
| LDLa | 3860..3894 | CDD:238060 | 2/33 (6%) | ||
| YncE | 3935..4148 | CDD:442618 | 66/216 (31%) | ||
| LY | 4108..4150 | CDD:214531 | 17/42 (40%) | ||
| EGF_CA | <4386..4414 | CDD:238011 | 9/50 (18%) | ||
| EGF_CA | 4415..4450 | CDD:238011 | 14/41 (34%) |